Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout

6

June 26 (Reuters) – Biogen said on Friday it had either paused or discontinued funding for most of Apellis Pharmaceuticals' research programs as it integrates the rare-disease drugs specialist it

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)